Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers followed a small group of people with highly drug-resistant virus taking Trogarzo plus an optimized background regimen.
Researchers gave the antibody treatment to those with multidrug-resistant HIV along with an optimized antiretroviral regimen.
Nelson Vergel pushes for the development of new salvage therapies.
The Food and Drug Administration approves antibody treatment Trogarzo for multidrug-resistant HIV.
The intravenous medication, which should be used with standard antiretrovirals, has a wholesale acquisition cost of $118,000 per year.
With an FDA decision for ibalizumab pending, data about a group with multidrug resistance show that the antibody is effective.
TaiMed Biologics has applied for approval of the weekly injectable antibody ibalizumab for people with multidrug-resistant virus.
TaiMed Biologics has applied for approval of the weekly injectable antibody ibalizumab for those with multidrug-resistant virus.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.